The GPC3 Knockout SK-HEP-1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the human SK-HEP-1 liver adenocarcinoma cell line, engineered to disrupt the GPC3 gene. This product delivers a heterogeneous pool of loss-of-function alleles, enabling robust functional interrogation of GPC3 in a hepatocellular carcinoma (HCC) context. As a polyclonal knockout resource, it circumvents clonal selection artifacts and provides immediate access to a broad spectrum of GPC3-deficient cells for parallel phenotypic and signaling analyses. The CRISPR/Cas9-mediated gene disruption targets the endogenous GPC3 locus, yielding a mixed population suitable for experiments requiring representation of diverse mutational outcomes while maintaining the parental line’s baseline characteristics.
SK-HEP-1 cells originate from a human liver adenocarcinoma and serve as a widely employed model for HCC. This adherent cell line retains hepatic features and exhibits aggressive tumorigenic properties in vitro and in xenograft assays, making it particularly relevant for studying liver cancer biology. The parental line expresses detectable levels of GPC3, along with components of Wnt, Hedgehog, FGF, and IGF signaling cascades, establishing a native molecular background for assessing GPC3-dependent phenotypes. Its use in cancer research spans drug sensitivity profiling, migration and invasion studies, and mechanistic dissection of oncogenic drivers.
GPC3 encodes glypican-3, a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan that functions as a co-receptor or modulator for multiple growth factor pathways. It interacts with Wnt3a and Frizzled receptors to potentiate Wnt/??-catenin signaling, leading to transcriptional activation of downstream targets such as MYC, CCND1, and AXIN2 by the ??-catenin/TCF complex. GPC3 also augments Hedgehog signaling through interaction with Hedgehog ligands, promoting GLI transcription factor-mediated gene expression. Additionally, it interfaces with FGF2 and IGF2, engaging the MAPK/ERK and Akt/mTOR axes. Its heparan sulfate chains and association with CD81 further facilitate signalosome assembly at the cell surface. Knockout of GPC3 disrupts these amplification mechanisms, attenuating oncogenic signaling.
In SK-HEP-1 cells, GPC3 overexpression is linked to enhanced proliferation, survival, and metastatic potential, consistent with its oncogenic role in HCC. Disruption of GPC3 in this polyclonal knockout model abrogates its co-receptor activity, thereby diminishing Wnt/??-catenin and Hedgehog pathway outputs. This results in reduced expression of proliferative and anti-apoptotic genes, impaired colony formation, and decreased migration. The model thus provides a physiologically relevant system to dissect GPC3-driven tumorigenicity and to explore crosstalk among signaling networks that converge on GPC3, including YAP/TAZ-mediated regulation. Moreover, it parallels aspects of Simpson-Golabi-Behmel syndrome, where GPC3 loss-of-function mutations cause overgrowth phenotypes, underscoring its dual role in development and cancer.
Researchers can employ these polyclonal knockout cells in a range of hypothesis-driven and translational applications. Western blotting and RT-qPCR confirm GPC3 disruption and downstream pathway alterations, while MTT and colony formation assays quantify proliferative changes. Transwell migration and xenograft tumor models assess metastatic capacity and in vivo tumor growth, respectively. Phospho-signaling analysis via flow cytometry or ELISA probes Akt, ERK, and ??-catenin activation status. RNA-seq experiments capture global transcriptomic shifts upon GPC3 loss, facilitating identification of novel targets. The cells are suitable for drug screening campaigns aimed at identifying compounds that bypass GPC3-mediated oncogenic signaling. For further information, please contact Ascent Research.
